From amino acid sequence to bioactivity: The biomedical potential of antitumor peptides

Protein Science

Volumn 25, Issue 6, 2016, Pages 1084-1095

  Blanco Míguez, Aitor ^a   Gutiérrez Jácome, Alberto ^a   Pérez Pérez, Martín ^a   Pérez Rodríguez, Gael ^a   Catalán García, Sandra ^b   Fdez Riverola, Florentino ^a   Lourenço, Anália ^a,c   Sánchez, Borja ^d  

^a UNIVERSITY OF VIGO   (Spain)

^b C/Jimena Fernández de la Vega ^*  (Spain)

^c UNIVERSITY OF MINHO   (Portugal)

^d DEPARTMENT OF MICROBIOLOGY AND BIOCHEMISTRY OF DAIRY PRODUCTS   (Spain)

Author keywords

antiproliferative; antitumoral; bioactive peptide; cancer; tumor

Indexed keywords

ACHE PEPTIDE; ADRENOMEDULLIN; AGGLUTININ; ANTITUMOR PEPTIDE; BETA CASEIN PHOSPHOPEPTIDE; BMK AGAP SYPU2; C TERMINAL FLANKING PEPTIDE OF PROGASTRIN; DOLASTATIN; HYD1 PEPTIDE; INTERLEUKIN 24; KLAK PEPTIDE; LACTOFERRICIN; MICROCIN E492; PATELLAMIDE A; PEPTIDE; PHAKELLISTATIN 10; PHAKELLISTATIN 14; PHAKELLISTATIN 2; PHAKELLISTATIN 4; PHAKELLISTATIN 5; PHAKELLISTATIN 6; PHAKELLISTATIN 7; PHAKELLISTATIN 8; PHAKELLISTATIN 9; PIGMENT EPITHELIUM DERIVED FACTOR; PROTEIN P160; PT PEPTIDE; TRUNKAMIDE A; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BIOLOGICAL ACTIVITY; CANCER INHIBITION; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CYTOTOXICITY; GENETIC TRANSCRIPTION; HUMAN; MIGRATION INHIBITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CELL MOTION; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN DATABASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL MOVEMENT; CELL PROLIFERATION; DATABASES, PROTEIN; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES;

EID: 84963957246     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2927     Document Type: Review

References (77)

1. Muzny DM, Bainbridge MN, Chang K, Dinh HH, Drummond JA, Fowler G, Kovar CL, Lewis LR, Morgan MB, Newsham IF, Reid JG, Santibanez J, Shinbrot E, Trevino LR, Wu Y-Q, Wang M, Gunaratne P, Donehower LA, Creighton CJ, Wheeler DA, Gibbs RA, Lawrence MS, Voet D, Jing R, Cibulskis K, Sivachenko A, Stojanov P, McKenna A, Lander ES, Gabriel S, Getz G, Ding L, Fulton RS, Koboldt DC, Wylie T, Walker J, Dooling DJ, Fulton L, Delehaunty KD, Fronick CC, Demeter R, Mardis ER, Wilson RK, Chu A, Chun H-JE, Mungall AJ, Pleasance E, Gordon Robertson A, Stoll D, Balasundaram M, Birol I, Butterfield YSN, Chuah E, Coope RJN, Dhalla N, Guin R, Hirst C, Hirst M, Holt RA, Lee D, Li HI, Mayo M, Moore RA, Schein JE, Slobodan JR, Tam A, Thiessen N, Varhol R, Zeng T, Zhao Y, Jones SJM, Marra MA, Bass AJ, Ramos AH, Saksena G, Cherniack AD, Schumacher SE, Tabak B, Carter SL, Pho NH, Nguyen H, Onofrio RC, Crenshaw A, Ardlie K, Beroukhim R, Winckler W, Getz G, Meyerson M, Protopopov A, Zhang J, Hadjipanayis A, Lee E, Xi R, Yang L, Ren X, Zhang H, Sathiamoorthy N, Shukla S, Chen P-C, Haseley P, Xiao Y, Lee S, Seidman J, Chin L, Park PJ, Kucherlapati R, Todd Auman J, Hoadley KA, Du Y, Wilkerson MD, Shi Y, Liquori C, Meng S, Li L, Turman YJ, Topal MD, Tan D, Waring S, Buda E, Walsh J, Jones CD, Mieczkowski PA, Singh D, Wu J, Gulabani A, Dolina P, Bodenheimer T, Hoyle AP, Simons J V., Soloway M, Mose LE, Jefferys SR, Balu S, O'Connor BD, Prins JF, Chiang DY, Neil Hayes D, Perou CM, Hinoue T, Weisenberger DJ, Maglinte DT, Pan F, Berman BP, Van Den Berg DJ, Shen H, Triche Jr T, Baylin SB, Laird PW, Getz G, Noble M, Voet D, Saksena G, Gehlenborg N, DiCara D, Zhang J, Zhang H, Wu C-J, Yingchun Liu S, Shukla S, Lawrence MS, Zhou L, Sivachenko A, Lin P, Stojanov P, Jing R, Park RW, Nazaire M-D, Robinson J, Thorvaldsdottir H, Mesirov J, Park PJ, Chin L, Thorsson V, Reynolds SM, Bernard B, Kreisberg R, Lin J, Iype L, Bressler R, Erkkil T, Gundapuneni M, Liu Y, Norberg A, Robinson T, Yang D, Zhang W, Shmulevich I, de Ronde JJ, Schultz N, Cerami E, Ciriello G, Goldberg AP, Gross B, Jacobsen A, Gao J, Kaczkowski B, Sinha R, Arman Aksoy B, Antipin Y, Reva B, Shen R, Taylor BS, Chan TA, Ladanyi M, Sander C, Akbani R, Zhang N, Broom BM, Casasent T, Unruh A, Wakefield C, Hamilton SR, Craig Cason R, Baggerly KA, Weinstein JN, Haussler D, Benz CC, Stuart JM, Benz SC, Zachary Sanborn J, Vaske CJ, Zhu J, Szeto C, Scott GK, Yau C, Ng S, Goldstein T, Ellrott K, Collisson E, Cozen AE, Zerbino D, Wilks C, Craft B, Spellman P, Penny R, Shelton T, Hatfield M, Morris S, Yena P, Shelton C, Sherman M, Paulauskis J, Gastier-Foster JM, Bowen J, Ramirez NC, Black A, Pyatt R, Wise L, White P, Bertagnolli M, Brown J, Chan TA, Chu GC, Czerwinski C, Denstman F, Dhir R, Dörner A, Fuchs CS, Guillem JG, Iacocca M, Juhl H, Kaufman A, Kohl III B, Van Le X, Mariano MC, Medina EN, Meyers M, Nash GM, Paty PB, Petrelli N, Rabeno B, Richards WG, Solit D, Swanson P, Temple L, Tepper JE, Thorp R, Vakiani E, Weiser MR, Willis JE, Witkin G, Zeng Z, Zinner MJ, Zornig C, Jensen MA, Sfeir R, Kahn AB, Chu AL, Kothiyal P, Wang Z, Snyder EE, Pontius J, Pihl TD, Ayala B, Backus M, Walton J, Whitmore J, Baboud J, Berton DL, Nicholls MC, Srinivasan D, Raman R, Girshik S, Kigonya PA, Alonso S, Sanbhadti RN, Barletta SP, Greene JM, Pot DA, Mills Shaw KR, Dillon LAL, Buetow K, Davidsen T, Demchok JA, Eley G, Ferguson M, Fielding P, Schaefer C, Sheth M, Yang L, Guyer MS, Ozenberger BA, Palchik JD, Peterson J, Sofia HJ, Thomson E, (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F, (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136: E359-E386.
3. Zheng LH, Wang YJ, Sheng J, Wang F, Zheng Y, Lin XK, Sun M, (2011) Antitumor peptides from marine organisms. Mar Drugs 9: 1840-1859.
4. Suarez-Jimenez GM, Burgos-Hernandez A, Ezquerra-Brauer JM, (2012) Bioactive peptides and depsipeptides with anticancer potential: sources from marine animals. Mar Drugs 10: 963-986.
5. Tyagi A, Tuknait A, Anand P, Gupta S, Sharma M, Mathur D, Joshi A, Singh S, Gautam A, Raghava GPS, (2015) CancerPPD: a database of anticancer peptides and proteins. Nucleic Acids Res 43: D837-D843.
6. Cheung CHA, Sun X, Kanwar JR, Bai J-Z, Cheng L, Krissansen GW, (2010) A cell-permeable dominant-negative survivin protein induces apoptosis and sensitizes prostate cancer cells to TNF-α therapy. Cancer Cell Int 10: 36.
7. Yuan Y, Zhang X, Weng S, Guan W, Xiang D, Gao J, Li J, Han W, Yu Y, (2014) Expression and purification of bioactive high-purity recombinant mouse SPP1 in Escherichia coli. Appl Biochem Biotechnol 173: 421-432.
8. Vacas E, Fernández-Martínez AB, Bajo AM, Sánchez-Chapado M, Schally AV, Prieto JC, Carmena MJ, (2012) Vasoactive intestinal peptide (VIP) inhibits human renal cell carcinoma proliferation. Biochim Biophys Acta 1823: 1676-1685.
9. Mas-Moruno C, Rechenmacher F, Kessler H, (2010) Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med Chem 10: 753-768.
10. Meikle ST, Perugini V, Guildford AL, Santin M, (2011) Synthesis, characterisation and in vitro anti-angiogenic potential of dendron VEGF blockers. Macromol Biosci 11: 1761-1765.
11. Jaseja M, Copié V, Starkey J, (2003) Conformational studies of antimetastatic laminin-1 derived peptides in different solvent systems, using solution NMR spectroscopy. J Pept Res 61: 24-39.
12. Onganer PU, Djamgoz MBA, Whyte K, Greenfield SA, (2006) An acetylcholinesterase-derived peptide inhibits endocytic membrane activity in a human metastatic breast cancer cell line. Biochim Biophys Acta 1760: 415-420.
13. Sroka TC, Marik J, Pennington ME, Lam KS, Cress AE, (2006) The minimum element of a synthetic peptide required to block prostate tumor cell migration. Cancer Biol Ther 5: 1556-1562.
14. Ek ETH, Dass CR, Contreras KG, Choong PFM, (2007) PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 25: 1671-1680.
15. Gürsoy RN, Çevik O, (2014) Design, characterization and in vitro evaluation of SMEDDS containing an anticancer peptide, linear LyP-1. Pharm Dev Technol 19: 486-490.
16. Dasgupta P, Singh A, Mukherjee R, (2002) N-terminal acylation of somatostatin analog with long chain fatty acids enhances its stability and anti-proliferative activity in human breast adenocarcinoma cells. Biol Pharm Bull 25: 29-36.
17. Dasgupta P, Singh AT, Mukherjee R, (1999) Antiproliferative and GH-inhibitory activity of chimeric peptides consisting of GHRP-6 and somatostatin. Biochem Biophys Res Commun 259: 379-384.
18. Shao JH, Cui Y, Zhao MY, Wu CF, Liu YF, Zhang JH, (2014) Purification, characterization, and bioactivity of a new analgesic-antitumor peptide from Chinese scorpion Buthus martensii Karsch. Peptides 53: 89-96.
19. Lin J-W, Jia J, Shen Y-H, Zhong M, Chen L-J, Li H-G, Ma H, Guo Z-F, Qi M-F, Liu L-X, Li T-L, (2013) Functional expression of FIP-fve, a fungal immunomodulatory protein from the edible mushroom Flammulina velutipes in Pichia pastoris GS115. J Biotechnol 168: 527-533.
20. Jiang YJ, Li QZ, Yan HB, Geng LJ, (2004) Expression and bioactivity analysis of recombinant beta-CPP dimer. J Dairy Sci 87: 3198-3208.
21. Mader JS, Richardson A, Salsman J, Top D, de Antueno R, Duncan R, Hoskin DW, (2007) Bovine lactoferricin causes apoptosis in Jurkat T-leukemia cells by sequential permeabilization of the cell membrane and targeting of mitochondria. Exp Cell Res 313: 2634-2650.
22. Marshall KM, Patel O, Bramante G, Laval M, Yim M, Baldwin GS, Shulkes A, (2013) The C-terminal flanking peptide of progastrin induces gastric cell apoptosis and stimulates colonic cell division in vivo. Peptides 46: 83-93.
23. Yang Z, Feng J, Li Y, Hu M, Song L, Yu M, Qin W, Shen B, (2005) Structure-based design and characterization of a Novel IL-6 antagonist peptide. Mol Immunol 42: 1015-1021.
24. Hetz C, Bono MR, Barros LF, Lagos R, (2002) Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines. Proc Natl Acad Sci USA 99: 2696-2701.
25. Lagos R, Tello M, Mercado G, García V, Monasterio O, (2009) Antibacterial and antitumorigenic properties of microcin E492, a pore-forming bacteriocin. Curr Pharm Biotechnol 10: 74-85.
26. Zhou W, Huang Y, Xu S, Gao Y, Chen W, Dong M, Yang Z, Xu T, (2013) Prokaryotic expression and bioactivity analysis of N-terminus domain of Pinellia ternata agglutinin using alkaline phosphatase signal peptide. Protein Expr Purif 89: 84-91.
27. Liu J-J, Zhang B-F, Yin X-X, Pei D-S, Yang Z-X, Di J-H, Chen F-F, Li H-Z, Xu W, Wu Y-P, Zheng J-N, (2012) Expression, purification, and characterization of RGD-mda-7, a his-tagged mda-7/IL-24 mutant protein. J Immunoassay Immunochem 33: 352-368.
28. Zhang BF, Liu JJ, Pei DS, Yang ZX, Di JH, Chen FF, Li HZ, Xu W, Wu YP, Zheng JN, (2011) Potent antitumor effect elicited by RGD-mda-7, an mda-7/IL-24 mutant, via targeting the integrin receptor of tumor cells. Cancer Biother Radiopharm 26: 647-655.
29. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, Chen X, Lee KC, (2011) Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 32: 3538-3546.
30. Kim TH, Jo YG, Jiang HH, Lim SM, Youn YS, Lee S, Chen X, Byun Y, Lee KC, (2012) PEG-transferrin conjugated TRAIL (TNF-related apoptosis-inducing ligand) for therapeutic tumor targeting. J Controlled Release 162: 422-428.
31. Askoxylakis V, Zitzmann S, Mier W, Graham K, Krämer S, von Wegner F, Fink RHA, Schwab M, Eisenhut M, Haberkorn U, (2005) Preclinical evaluation of the breast cancer cell-binding peptide, p160. Clin Cancer Res 11: 6705-6712.
32. Standley SM, Toft DJ, Cheng H, Soukasene S, Chen J, Raja SM, Band V, Band H, Cryns VL, Stupp SI, (2010) Induction of cancer cell death by self-assembling nanostructures incorporating a cytotoxic peptide. Cancer Res 70: 3020-3026.
33. Pettit GR, Tan R, Ichihara Y, Williams MD, Doubek DL, Tackett LP, Schmidt JM, Cerny RL, Boyd MR, Hooper JN, (1995) Antineoplastic agents, 325. Isolation and structure of the human cancer cell growth inhibitory cyclic octapeptides phakellistatin 10 and 11 from Phakellia sp. J Nat Prod 58: 961-965.
34. Milne BF, Long PF, Starcevic A, Hranueli D, Jaspars M, (2006) Spontaneity in the patellamide biosynthetic pathway. Org Biomol Chem 4: 631-638.
35. Anon (1997) Isolation and structural elucidation of the human cancer cell growth inhibitory cyclic peptides phakellistatin 4, 5, 6, 7, 8 and 9. Available from: http://www.google.com/patents/US5646246. Last accessed on January 20, 2016.
36. Jiang J, Deng L, He L, Liu H, Wang C, (2011) Expression, purification, refolding, and characterization of octreotide-interleukin-2: a chimeric tumor-targeting protein. Int J Mol Med 28: 549-556.
37. Barna BP, Thomassen MJ, Zhou P, Pettay J, Singh-Burgess S, Deodhar SD, (1996) Activation of alveolar macrophage TNF and MCP-1 expression in vivo by a synthetic peptide of C-reactive protein. J Leukocyte Biol 59: 397-402.
38. Kranenburg O, Kroon-Batenburg LMJ, Reijerkerk A, Wu YP, Voest EE, Gebbink MFBG, (2003) Recombinant endostatin forms amyloid fibrils that bind and are cytotoxic to murine neuroblastoma cells in vitro. FEBS Lett 539: 149-155.
39. Hibino S, Shibuya M, Engbring JA, Mochizuki M, Nomizu M, Kleinman HK, (2004) Identification of an active site on the laminin alpha5 chain globular domain that binds to CD44 and inhibits malignancy. Cancer Res 64: 4810-4816.
40. Li H, Jiang X, Howell SB, Goodman M, (2000) Synthesis, conformational analysis and bioactivity of Lan-7, a lanthionine analog of TT-232. J Pept Sci 6: 26-35.
41. Chen J-H, Zhang X-G, Jiang Y-T, Yan L-Y, Tang L, Yin Y-W, Cheng D-S, Chen J, Wang M, (2010) Bioactivity and pharmacokinetics of two human serum albumin-thymosin alpha1-fusion proteins, rHSA-Talpha1 and rHSA-L-Talpha1, expressed in recombinant Pichia pastoris. Cancer Immunol Immunother 59: 1335-1345.
42. Fernández-Tomé S, Ramos S, Cordero-Herrera I, Recio I, Goya L, Hernández-Ledesma B, (2014) In vitro chemo-protective effect of bioactive peptide lunasin against oxidative stress in human HepG2 cells. Food Res Int 62: 793-800.
43. Line BR, Mitra A, Nan A, Ghandehari H, (2005) Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 46: 1552-1560.
44. Lainchbury JG, Cooper GJ, Coy DH, Jiang NY, Lewis LK, Yandle TG, Richards AM, Nicholls MG, (1997) Adrenomedullin: a hypotensive hormone in man. Clin Sci 92: 467-472.
45. Behera B, Devi KSP, Mishra D, Maiti S, Maiti TK, (2014) Biochemical analysis and antitumour effect of Abrus precatorius agglutinin derived peptides in Ehrlich's ascites and B16 melanoma mice tumour model. Environ Toxicol Pharmacol 38: 288-296.
46. Murray BA, FitzGerald RJ, (2007) Angiotensin converting enzyme inhibitory peptides derived from food proteins: biochemistry, bioactivity and production. Curr Pharm Des 13: 773-791.
47. Annese C, Abbrescia DI, Catucci L, D'Accolti L, Denora N, Fanizza I, Fusco C, La Piana G, (2013) Site-dependent biological activity of valinomycin analogs bearing derivatizable hydroxyl sites. J Pept Sci 19: 751-757.
48. Ayers S, Ehrmann BM, Adcock AF, Kroll DJ, Carcache de Blanco EJ, Shen Q, Swanson SM, Falkinham JO, Wani MC, Mitchell SM, Pearce CJ, Oberlies NH, (2012) Peptaibols from two unidentified fungi of the order Hypocreales with cytotoxic, antibiotic, and anthelmintic activities. J Pept Sci 18: 500-510.
49. Ravichandran S, Wahidullah S, D'souza L, Anbuchezhian RM, (2011) Antimicrobial activity of marine sponge Clathria indica (Dendy, 1889). Russ J Bioorg Chem 37: 428-435.
50. Wrasidlo W, Mielgo A, Torres VA, Barbero S, Stoletov K, Suyama TL, Klemke RL, Gerwick WH, Carson DA, Stupack DG, (2008) The marine lipopeptide somocystinamide A triggers apoptosis via caspase 8. Proc Natl Acad Sci USA 105: 2313-2318.
51. Möller NP, Scholz-Ahrens KE, Roos N, Schrezenmeir J, (2008) Bioactive peptides and proteins from foods: indication for health effects. Eur J Nutr 47: 171-182.
52. Lafarga T, Hayes M, (2014) Bioactive peptides from meat muscle and by-products: generation, functionality and application as functional ingredients. Meat Sci 98: 227-239.
53. Ryan JT, Ross RP, Bolton D, Fitzgerald GF, Stanton C, (2011) Bioactive peptides from muscle sources: meat and fish. Nutrients 3: 765-791.
54. Hernandez-Ledesma B, Hsieh CC, de Lumen BO, (2013) Chemopreventive properties of Peptide Lunasin: a review. Protein Pept Lett 20: 424-432.
55. Erdmann K, Cheung BWY, Schröder H, (2008) The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease. J Nutr Biochem 19: 643-654.
56. Bae SM, Kim JH, Chung SW, Byun Y, Kim SY, Lee BH, Kim IS, Park RW, (2013) An apoptosis-homing peptide-conjugated low molecular weight heparin-taurocholate conjugate with antitumor properties. Biomaterials 34: 2077-2086.
57. Bifulco M, Laezza C, Valenti M, Ligresti A, Portella G, DI Marzo V, (2004) A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606-1608.
58. Costa A, Scholer-Dahirel A, Mechta-Grigoriou F, (2014) The role of reactive oxygen species and metabolism on cancer cells and their microenvironment. Semin Cancer Biol 25: 23-32.
59. Jumeri KSM, (2011) Antioxidant and anticancer activities of enzymatic hydrolysates of solitary tunicate (Styela clava). Food Sci Biotechnol 20: 1075-1085.
60. Ando K, Shimosawa T, Fujita T, (2004) Adrenomedullin in vascular diseases. Curr Hypertens Rep 6: 55-59.
61. Marino G, Niso-Santano M, Baehrecke EH, Kroemer G, (2014) Self-consumption: the interplay of autophagy and apoptosis. Nat Rev Mol Cell Biol 15: 81-94.
62. Visvader JE, (2011) Cells of origin in cancer. Nature 469: 314-322.
63. Islam MN, Iskander MN, (2004) Microtubulin binding sites as target for developing anticancer agents. Mini Rev Med Chem 4: 1077-1104.
64. Cruz-Monserrate Z, Mullaney JT, Harran PG, Pettit GR, Hamel E, (2003) Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography. Eur J Biochem 270: 3822-3828.
65. Rayaprolu SJ, Hettiarachchy NS, Chen P, Kannan A, Mauromostakos A, (2013) Peptides derived from high oleic acid soybean meals inhibit colon, liver and lung cancer cell growth. Food Res Int 50: 282-288.
66. Hamada Y, Shioiri T, (2005) Recent progress of the synthetic studies of biologically active marine cyclic peptides and depsipeptides. Chem Rev 105: 4441-4482.
67. Noguchi M, Arai G, Matsumoto K, Naito S, Moriya F, Suekane S, Komatsu N, Matsueda S, Sasada T, Yamada A, Kakuma T, Itoh K, (2015) Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. Cancer Immunol Immunother 64: 493-505.
68. Prue RL, Vari F, Radford KJ, Tong H, Hardy MY, D'Rozario R, Waterhouse NJ, Rossetti T, Coleman R, Tracey C, Goossen H, Gounder V, Crosbie G, Hancock S, Diaz-Guilas S, Mainwaring P, Swindle P, Hart DNJ, (2015) A phase I clinical trial of CD1c (BDCA-1)+ dendritic cells pulsed with HLA-A∗0201 peptides for immunotherapy of metastatic hormone refractory prostate cancer. J Immunother 38: 71-76.
69. Thundimadathil J, (2012) Cancer treatment using peptides: current therapies and future prospects. J Amino Acids 2012: 967347.
70. Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y, (2015) Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 106: 883-890.
71. Matsuyama M, Ishii H, Furuse J, Ohkawa S, Maguchi H, Mizuno N, Yamaguchi T, Ioka T, Ajiki T, Ikeda M, Hakamada K, Yamamoto M, Yamaue H, Eguchi K, Ichikawa W, Miyazaki M, Ohashi Y, Sasaki Y, (2015) Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer. Invest New Drugs 33: 490-495.
72. Galsky MD, Vogelzang NJ, Conkling P, Polzer J, Roberson S, Stille JR, Saleh M, Thornton D, (2014) A phase I trial of LY2510924, a CXCR4 peptide antagonist, in patients with advanced cancer. Clin Cancer Res 20: 3581-3588.
73. Iagaru A, Mosci C, Shen B, Chin FT, Mittra E, Telli ML, Gambhir SS, (2014) (18)F-FPPRGD2 PET/CT: pilot phase evaluation of breast cancer patients. Radiology 273: 549-559.
74. Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C, (2010) Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. Eur J Cancer 46: 2746-2752.
75. Lorusso D, Scambia G, Amadio G, di Legge a, Pietragalla a, De Vincenzo R, Masciullo V, Di Stefano M, Mangili G, Citterio G, Mantori M, Lambiase a, Bordignon C, (2012) Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients. Br J Cancer 107: 37-42.
76. Edelman MJ, Clamon G, Kahn D, Magram M, Lister-James J, Line BR, (2009) Targeted radiopharmaceutical therapy for advanced lung cancer: phase I trial of rhenium Re188 P2045, a somatostatin analog. J Thorac Oncol 4: 1550-1554.
77. Gordon MS, Mendelson D, Carr R, Knight RA, Humerickhouse RA, Iannone M, Stopeck AT, (2008) A phase 1 trial of 2 dose schedules of ABT-510, an antiangiogenic, thrombospondin-1-mimetic peptide, in patients with advanced cancer. Cancer 113: 3420-3429.